New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
11:04 EDTIMMUImmunomedics reports results from three IMMU-130 phase I trials
Immunomedics reported the results from 3 Phase I trials with IMMU-130, the company's investigational anti-CEACAM5 antibody conjugated to the irinotecan-metabolite, SN-38. The antibody-drug conjugate was therapeutically active in all 3 trials, but a more frequent dosing schedule, with administrations of IMMU-130 once or twice-weekly for 2 weeks followed by a week off, was more active in patients with metastatic colorectal cancer than when administered every other week. Results from these Phase I studies were presented at the 2014 Annual Meeting of the American Association for Cancer Research in San Diego, CA, by a group of clinical investigators. In all three trials, measurement of SN-38 concentrations in the serum found much higher levels that were sustained longer than is typically found with irinotecan therapy, the parental drug of SN-38. However, most of the SN-38 remains bound to the antibody, keeping it in an inactive form to normal tissues while in circulation, which reduces toxicity, yet allowing for higher concentrations of activated SN-38 to be delivered to the tumor where it is released from the pH- sensitive linker. Neutropenia and manageable diarrhea were the main side effects. "These results suggest that IMMU-130 may have a high therapeutic index and can be administered in repeated cycles in advanced mCRC patients," commented CEO Cynthia Sullivan.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
08:35 EDTIMMUImmunomedics announces dismissal of class action lawsuit
Subscribe for More Information
January 20, 2015
08:46 EDTIMMUImmunomedics reports Phase 1/2 results with sacituzumab govitecan
Immunomedics announced that sacituzumab govitecan, the company's lead investigational antibody-drug conjugate, or ADC, produces partial response, or PR, in some patients with metastatic esophageal and colorectal cancers who had been heavily pretreated. Extended periods of stable disease were also noted in some patients with pancreatic and gastric cancers, with time-to-progression, or TTP, exceeding that of last prior therapy in many cases. Response and TTP were evaluated by computed tomography, or CT, based on RECIST criteria. Patented and developed by the company, sacituzumab govitecan was created by conjugating the moderately-toxic drug, SN-38, site-specifically and at a high ratio of drug to antibody to a humanized antibody that targets the TROP-2 receptor expressed by many solid cancers. SN-38 is the active metabolite of irinotecan, which is used to treat certain solid cancers, particularly metastatic colorectal cancers, as a part of combination therapies, so its pharmacology and properties are well-known. Despite the late-stage setting, 1 patient in each of the colorectal and esophageal cancer groups had a partial response after receiving more than 2 doses of the ADC. For all 4 cancer types, the disease stabilization rate exceeded 50%.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use